(Q40745292)

23 September 2017

1 reference

title

Is vaccination against hepatitis B efficient? A review of world literature (English)

1 reference

23 September 2017

Jefferson T

1

1 reference

PubMed ID

8167797

23 September 2017

Demicheli V

series ordinal

2

1 reference

PubMed ID

8167797

23 September 2017

language of work or name

English

0 references

publication date

1 January 1994

1 reference

23 September 2017

1 reference

23 September 2017

3

1 reference

23 September 2017

1

1 reference

23 September 2017

25-37

1 reference

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

23 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

Routine hepatitis screening in adolescent pregnancies: is it cost effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B virus vaccine. Cost-benefit analysis of its use in a children's hospital

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B virus vaccine. An analysis of its potential use in medical workers

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Publication bias in clinical research

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Searching the literature. Be systematic in your searching

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost-benefit analysis of hepatitis-B vaccination

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost-Effectiveness of Hepatitis-B Vaccine in Greece: A Country of Intermediate HBV Endemicity

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Immunogenicity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost effectiveness of antenatal hepatitis B screening and vaccination of infants

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost effectiveness of intradermal vs. subcutaneous hepatitis b vaccination for the mentally handicapped

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Low-cost hepatitis B vaccine improves uptake among self-paying health-care students

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Formula for calculating vaccine profitability.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B vaccination for staff in institutions for the mentally handicapped

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B virus eradication strategy for Asia. The Asian Regional Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B vaccine and hepatitis B markers: cost effectiveness of screening prehospital personnel

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost-effectiveness of hepatitis B vaccine in The Gambia.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Effectiveness of intradermal hepatitis B immunization of hospital staff

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B infection in sub-Saharan Africa. The African Regional Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Should your hospital's employees receive pantitis B vaccine?

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

HBV pre-vaccination screening in hospital personnel: cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B prevention strategies: a benefit-cost analysis of immune serum globulin, hepatitis B immune globulin, and hepatitis B vaccine in the military

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Occupational risk of hepatitis B from institutionalized mentally retarded HBsAg carriers: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost of plasma-derived hepatitis B vaccine production.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Exposure of the wound--a safe economy in the NHS

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B vaccine for health care personnel

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Costs and benefits of the passive prophylaxis of hepatitis B in an Italian hospital

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Hepatitis B prevention. Part 1: A review of ACIP's newest guidelines.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost analysis of a needle stick protocol

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Benefits and costs of vaccination

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Cost benefit of vaccination for hepatitis B in hemodialysis centers

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730030105

7 January 2021

Identifiers

DOI

10.1002/HEC.4730030105

1 reference

23 September 2017

1 reference

PubMed ID

8167797